@article{10902/32005,
year = {2024},
url = {https://hdl.handle.net/10902/32005},
abstract = {Thoracic aortic aneurysm and dissection (TAAD) is a life-threatening condition associated with Marfan syndrome (MFS), a disease caused by fibrillin-1 gene mutations. While various conditions causing TAAD exhibit aortic accumulation of the proteoglycans versican (Vcan) and aggrecan (Acan), it is unclear whether these ECM proteins are involved in aortic disease. Here, we find that Vcan, but not Acan, accumulated in Fbn1C1041G/+ aortas, a mouse model of MFS. Vcan haploinsufficiency protected MFS mice against aortic dilation, and its silencing reverted aortic disease by reducing Nos2 protein expression. Our results suggest that Acan is not an essential contributor to MFS aortopathy. We further demonstrate that Vcan triggers Akt activation and that pharmacological Akt pathway inhibition rapidly regresses aortic dilation and Nos2 expression in MFS mice. Analysis of aortic tissue from MFS human patients revealed accumulation of VCAN and elevated pAKT-S473 staining. Together, these findings reveal that Vcan plays a causative role in MFS aortic disease in vivo by inducing Nos2 via Akt activation and identify Akt signaling pathway components as candidate therapeutic targets.},
organization = {Acknowledgements: We thank S. Bartlett for English language editing; V Labrador for advice on confocal imaging and immunofluorescent experiments; the CNIC Facilities of histology, microscopy, and advanced imaging; and AI Torralbo for excellent technical support and advice. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), the CBMSO is supported by Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid. CBMSO and CNIC are Severo Ochoa Centers of Excellence (grants CEX2021-001154-S and CEX2020-001041-S, respectively) funded by MICIN/AEI/10.13039/ 501100011033. The project leading to these results has received funding from “La Caixa” Banking Foundation under project codes HR18-00068 (to MRC and JMR); Spanish Ministerio de Ciencia e Innovación grant RTI2018-099246-BI00 (MICIU/AEI/FEDER, UE) to JMR, and grants PID2020-115217RB-100 and PID2021-122388OB-100 to MRC and JMR, respectively, funded by MCIN/AEI/ 10.13039/501100011033; Instituto de Salud Carlos III (CIBER-CV CB16/11/ 00264 and CB16/11/00479; and grants PI17/00381 to GT-T and PI21/00084 (co-funded by Fondo Europeo de Desarrollo Regional (FEDER)) to JFN); Fundacio La Marato TV3 (20151330 to JMR); Instituto de Investigación Sanitaria Marqués de Valdecilla (IDIVAL) (INNVAL 21/24) to JFN; The Marfan Foundation USA Faculty grant 2017 MRF/1701 (to JMR); Fundación MERCKFundación Española de Enfermedades Raras 2022 and V-Ayudas “Muevete por ́ los que no pueden 2021” (to JO); and Spanish Ministerio de Ciencia e Innovación contracts FPI (BES-2016-077649) to MJR-R; Sara Borrell (CD18/ 00028) and Juan de la Cierva (IJC2020-044581-I) to MT; Ramón y Cajal (RYC2021-033343-I) to JO; and FPU (20/04814) to IA-R.},
publisher = {Wiley-Blackwell},
publisher = {EMBO Molecular Medicine, 2024, 
16, 132-157},
title = {Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation},
author = {Ruiz-Rodríguez, María Jesús and Oller, Jorge and Martínez-Martínez, Sara and Alarcón-Ruiz, Iván and Toral, Marta and Sun, Yilin and Colmenar, Ángel and Méndez-Olivares, María José and López-Maderuelo, Dolores and Kern, Christine B. and Nistal Herrera, Juan Francisco and Evangelista, Arturo and Teixido-Tura, Gisela and Campanero, Miguel R. and Redondo, Juan Miguel},
}